| Literature DB >> 34948623 |
Carmen Sáez1,2, Alfredo Sánchez1, Vicent Yusà3,4,5, Pablo Dualde3, Sandra F Fernández3,5, Antonio López3, Francisca Corpas-Burgos3, Miguel Ángel Aguirre2, Clara Coscollà3.
Abstract
This case study investigates the exposure of 119 Spanish women of reproductive age to 5 essential (Co, Cu, Mn, V, Zn) and 10 toxic (Ba, Be, Cs, Ni, Pb, Pt, Sb, Th, Al, U) elements and assesses their risk. The essential elements (Co, Cu, Mn, V, and Zn) showed average concentrations (GM: geometric mean) of 0.8, 35, 0.5, 0.2, and 347 μg/L, respectively. Five of the toxic elements (Ba, Cs, Ni, Al, U) exhibited detection frequencies of 100%. The GM concentrations of the novel toxic elements were 12 μg/L (Al), 0.01 μg/L (Pt), 0.02 μg/L (U), 0.12 μg/L (Th), 0.009 μg/L (Be) and 4 μg/L (Cs). The urine analysis was combined with a survey to assess any variations between subgroups and potential predictors of exposure to elements in the female population. Significant differences were obtained between the rural and urban areas studied for the toxic element Cs, with higher levels found in mothers living in urban areas. In relation to diet, statistically significantly higher levels of essential (Cu) and toxic (Ba) elements were detected in women with a high consumption of fish, while mothers who consumed a large quantity of legumes presented higher levels of the toxic element Ni (p = 0.0134). In a risk-assessment context, hazard quotients (HQs) greater than 1 were only observed for the essential elements Zn and Cu in P95. No deficiency was found regarding the only essential element for which a biomonitoring equivalent for nutritional deficit is available (Zn). For the less-studied toxic elements (Al, Pt, U, Th, Be, and Cs), HQs were lower than 1, and thus, the health risk due to exposure to these elements is expected to be low for the female population under study.Entities:
Keywords: biomonitoring; elements; risk assessment; urine; women
Mesh:
Substances:
Year: 2021 PMID: 34948623 PMCID: PMC8701213 DOI: 10.3390/ijerph182413012
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Urinary excretion factors and health-based reference values of the elements used for the risk assessment.
| Metal Group | Element | FUE | Health-Based Reference Value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Value | Considerations | Ref. | Value | Type | Units | Considerations | Ref. | ||
| Essential metals | Co | 0.019 (mean of 2 values) | Mostly excreted in feces after oral administration | [ | 30 | RfD | μg/kg/day | POD/30 | [ |
| Cu | 0.018 (mean of 2 values) | Mostly excreted in bile after oral administration. Data of urinary excretion after daily intake. At high Cu intakes, urinary Cu excretion increases | [ | 5 | UL (EFSA) | mg/day | NOAEL/2 | [ | |
| Mn | NF | Mn is mainly excreted in feces. Urinary excretion of Mn is not related with oral intake | [ | NF | NF | NF | Owing to limitations | [ | |
| V | 0.009 | Study with rats. Data of 7-day cumulative excretion after oral administration as sodium metavanadate. Mostly excreted unabsorbed in feces after oral administration. After inhalation V is mainly excreted in urine. | [ | 1.8 | UL | mg/day | UL for ≥19 years | [ | |
| Zn | NA | NA | NA | 159 (204) | BE for deficiency | μg/L (μg/g) | Based on IOM EAR (nutritional) for women (0.1 mg/kg/day) | [ | |
| 439 (564) and 1316 (1693) | BE and BEPOD for toxicity | μg/L (μg/g) | ATSDR chronic MRL (0.3 mg/kg/day) 1 | ||||||
| Toxic metals 2 | Ba | NA | NA | NA | 192 (5.74) | BE (BEPOD) | μg/L (mg/L) | Based on U.S. EPA’s RfD (0.2 mg/kg/day) | [ |
| 246 (7.39) | μg/g (mg/g) | ||||||||
| Cs | 0.10 (mean of 2 values) 3 | Data of 7-day cumulative excretion after oral administration as cesium chloride | [ | NF | NF | NF | NF | NF | |
| Ni | 0.04 (24 h) | Based on ingested dose of Ni chloride in rats | [ | 13 | TDI | μg/kg/day | Oral exposure | [ | |
| Pb | 0.12 (24 h) | Based on ingested dose. Mostly excreted in feces. | [ | 0.63 | BMDL10 | μg/kg/day | Renal Effects, oral exposure | [ | |
| Pt | 0.51 (mean of 2 values, 24 h) | Approximation. Based on diet studies. | [ | 2.6 | PDE | μg/kg/day | Oral exposure | [ | |
| Sb | 0.55 (mean of 2 values, 24 h) | Based on intravenous injection in humans | [ | 0.4 | RfD | μg/kg/day | Hematologic, oral exposure | [ | |
| Th | 0.025 (24 h) | Mostly excreted in feces | [ | NF | NF | NF | NF | NF | |
| Al | NA | NA | NA | 57 (20500) | BE (BEPOD) | μg/L, μg/g | Based on LOAEL (50 mg/kg/day) | [ | |
| U | 0.05 (24 h) | Based on ingested dose. Mostly excreted in feces. | [ | 0.6 | TDI | μg/kg/day | Oral exposure | [ | |
1 The lowest derived value was selected; 2 Be was not assessed due to its low DF (<40%); 3 Data derived from total excretion and urinary/fecal excretion ratios; Ref: reference; POD: point of departure; RfD: reference dose; UL: tolerable upper intake level; BMDL10: benchmark dose lower confidence limit, resulting in a 10% extra cancer incidence; PDE: permitted daily exposure; NA: not applicable; NF: not found.
Frequency of detection and levels of elements (μg/L) in the urine of women from the Valencian Region (N = 119) 1. Creatinine-adjusted urinary levels (μg/g creat) 1.
| Element | DF % | Minimum | P25 | Median | AM | GM | P75 | P95 | Maximum | SD |
|---|---|---|---|---|---|---|---|---|---|---|
| Al | 100 | 2.9 (2.2) | 9 (8) | 12 (12) | 15(16) | 12 (12) | 15 (17) | 29 (32) | 164 (139) | 17 (18) |
| Ba | 100 | 0.13 (0.09) | 1.2 (1.1) | 2.0 (1.9) | 2.7 (2.6) | 1.9 (1.9) | 3.0 (3.5) | 7.3 (7.0) | 17.2 (12.9) | 2.7 (2.2) |
| Be | 32 | 0.002 (0.002) | 0.006 (0.005) | 0.008 (0.009) | 0.01 (0.01) | 0.009 (0.009) | 0.01 (0.01) | 0.02 (0.03) | 0.03 (0.04) | 0.007 (0.009) |
| Co | 100 | 0.2 (0.3) | 0.6 (0.6) | 0.8 (0.8) | 1.0 (1.0) | 0.8 (0.9) | 1.2 (1.1) | 2.4 (2.1) | 4.7 (3.1) | 0.8 (0.5) |
| Cs | 100 | 1.1 (1.6) | 3 (3) | 4 (4) | 5 (4) | 4 (4) | 6 (5) | 10 (8) | 15 (15) | 3 (2) |
| Cu | 100 | 9 (15) | 24 (28) | 35 (35) | 43 (40) | 35 (35) | 53 (41) | 79 (66) | 400 (268) | 42 (28) |
| Mn | 100 | 0.02 (0.04) | 0.4 (0.3) | 0.5 (0.5) | 0.6 (0.6) | 0.5 (0.5) | 0.7 (0.7) | 1.4 (1.4) | 2.4 (3.4) | 0.4 (0.5) |
| Ni | 100 | 0.8 (1.0) | 3 (3) | 4 (4) | 6 (5) | 4 (4) | 6 (6) | 14 (10) | 38 (42) | 5 (5) |
| Pb | 99 | 0.02 (0.02) | 0.5 (0.6) | 0.8 (0.9) | 1.0 (0.9) | 0.8 (0.8) | 1.3 (1.1) | 1.9 (1.6) | 3.2 (2.6) | 0.6 (0.4) |
| Pt | 81 | 0.001 (0.001) | 0.007 (0.005) | 0.01 (0.01) | 0.02 (0.02) | 0.01 (0.01) | 0.02 (0.02) | 0.07 (0.05) | 0.21 (0.11) | 0.02 (0.02) |
| Sb | 97 | 0.007 (0.009) | 0.05 (0.05) | 0.10 (0.09) | 0.12 (0.11) | 0.09 (0.09) | 0.16 (0.15) | 0.27 (0.23) | 0.55 (0.29) | 0.09 (0.06) |
| Th | 98 | 0.01 (0.02) | 0.04 (0.04) | 0.14 (0.13) | 0.17 (0.19) | 0.12 (0.12) | 0.23 (0.26) | 0.43 (0.54) | 1.12 (0.80) | 0.16 (0.18) |
| U | 100 | 0.005 (0.006) | 0.02 (0.02) | 0.02 (0.02) | 0.03 (0.03) | 0.02 (0.02) | 0.03 (0.03) | 0.06 (0.07) | 0.13 (0.09) | 0.02 (0.02) |
| V | 79 | 0.004 (0.004) | 0.09(0.10) | 0.3 (0.3) | 0.4 (0.3) | 0.2 (0.2) | 0.5 (0.4) | 0.84 (0.89) | 1.92 (2.91) | 0.31 (0.36) |
| Zn | 100 | 71 (80) | 230 (250) | 343 (353) | 417 (389) | 347 (348) | 560 (491) | 848 (705) | 1526 (1078) | 259 (184) |
1 Left censored data (˂LoQ) were imputed, according to the maximum likelihood estimation method (See Section 2.5). DF: frequency of detection; AM: arithmetic mean; GM: geometric mean; SD: standard deviation.
Figure 1Histograms for some investigated elements (Ba, Co, Cs, Cu, Mn, Ni, Pb, Sb, V, Zn, and U). GM: geometric mean.
Results of the multiple linear regression models for log (elements) concentrations in the urine of Spanish women.
| Metals | Factors | Estimated Coefficients (95% CI) | Standard Error | |
|---|---|---|---|---|
| Cs | Place of residence (last 10 years): | |||
| Urban | - | - | - | |
| Rural | −0.1913 (−0.3659–−0.0168) | 0.088 | 0.032 | |
| Creatinine (mg/dL) | 0.9526 (0.7998–1.1055) | 0.0771 | <0.001 | |
| Ni | Legumes (nº portions 72 h) | 0.1586 (0.0335–0.2836) | 0.0631 | 0.013 |
| Creatinine (mg/dL) | 0.6844 (0.4693–0.8996) | 0.1085 | <0.001 | |
| Cu | Fish (nº portions 72 h) | 0.146 (0.0433–0.2488) | 0.0518 | 0.006 |
| Creatinine (mg/dL) | 0.8887 (0.7246–1.0529) | 0.0828 | <0.001 | |
| Ba | Shellfish (nº portions 72 h) | 0.355 (0.0695–0.6405) | 0.144 | 0.015 |
| Creatinine (mg/dL) | 0.6113 (0.2779–0.9447) | 0.1682 | <0.001 | |
| Co | Creatinine (mg/dL) | 0.8458 (0.6641–1.0276) | 0.0917 | <0.001 |
| Mn | Creatinine (mg/dL) | 0.3297 (0.0889–0.5706) | 0.1215 | 0.008 |
| Pb | Creatinine (mg/dL) | 0.9146 (0.6654–1.1638) | 0.1257 | <0.001 |
| Sb | Creatinine (mg/dL) | 0.9212 (0.6642–1.1782) | 0.1297 | <0.001 |
| V | Creatinine (mg/dL) | 0.5437 (0.1082–0.9792) | 0.2197 | 0.015 |
| Zn | Creatinine (mg/dL) | 0.7762 (0.5853–0.9672) | 0.0963 | <0.001 |
| U | Creatinine (mg/dL) | 0.4267 (0.2349–0.6186) | 0.0968 | <0.001 |
1p-value ≤ 0.05.
Estimated daily intake for some of the assessed elements.
| Group | Metal | EDI Based on Volume (μg/kg/day) | EDI Based on Creatinine (μg/kg/day) | ||
|---|---|---|---|---|---|
| EDIGM | EDIP95 | EDIGM | EDIP95 | ||
| Essential metals 1 | Co | 1.2 | 3.4 | 0.77 | 1.87 |
| Cu | 54 | 120 | 35 | 64 | |
| V | 0.6 | 2.5 | 0.4 | 1.7 | |
| Toxic metals 2 | Cs | 1.1 | 2.6 | 0.68 | 1.69 |
| Ni | 2.9 | 9.3 | 1.8 | 4.5 | |
| Pb | 0.18 | 0.43 | 0.11 | 0.23 | |
| Pt | 0.0005 | 0.0037 | 0.0003 | 0.0017 | |
| Sb | 0.004 | 0.013 | 0.003 | 0.007 | |
| Th | 0.13 | 0.46 | 0.08 | 0.29 | |
| U | 0.011 | 0.032 | 0.007 | 0.024 | |
EDIs for Zn, Ba and Al were not calculated since we used the BE concept for risk assessment. 1 Mn was not assessed due to the lack of information about its excretion urinary factor. 2 Be was not assessed due to its low DF (<40%).
Figure 2Hazard quotients for some metal concentrations based on volume (a) and creatinine (b). GM: geometric mean; P95: 95th percentile.
Comparative data on levels of metals in women’s urine in other studies.
| Study | Country | Year | Population/ | N | Age (Years) | AM | GM | |
|---|---|---|---|---|---|---|---|---|
| Essential Elements | ||||||||
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 43.67 μg/L | 35.36 μg/L | |
| [ | Japan (11 prefectures) | 2000–2005 | Women (n.o.) | 1000 | 20–81 | - | 13.4 μg/L | |
| [ | Japan | 2007–2008 | Pregnant women | 78 | - | 12.8 μg/g creat | ||
| [ | Canada (Quebec) | 2009–2011 | Women | 2992 | 6–79 | - | 10.0 μg/L | |
| [ | Belgium | 2010–2011 | general population | 1022 | >18 | 6.94 μg/L | ||
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 1.04 μg/L | 0.84 μg/L | |
| [ | Italy (urban areas) | - | Healthy subjects | 44 | - | 0.0009 μg/L | - | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.60 μg/L | 0.49 μg/L | |
| [ | Pakistan | 1999–2005 | Women | 166 | 45–75 | 1.55 μg/L | - | |
| [ | Japan (11 prefectures) | 2000–2005 | Women (n.o.) | 1000 | 20–81 | - | 0.14 μg/L | |
| [ | NHANES (USA) | 2011–2016 | Women | - | 14–45 | - | 0.14 μg/g creat | |
| [ | New Mexico (USA) | 2010 | Pregnant women | 448 | 14–45 | - | 0.30 μg/g creat | |
| [ | Riyadh (Saudi Arabia) | 2011–2013 | Lactating women | 198 | 19–45 | - | 2.42 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 417.29 μg/L | 347.25 μg/L | |
| [ | Italy (urban areas) | - | Healthy subjects | 44 | - | 0.0012 μg/L | - | |
| [ | Belgium | 2010–2011 | General population | 1022 | >18 | - | 227 μg/L | |
| [ | Japan | 2007–2008 | Pregnant women | 78 | - | 393 μg/g creat | ||
| [ | Canada (Quebec) | 2009–2011 | women | 2992 | 6–79 | - | 250 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.35 μg/L 0.34 μg/g creat | 0.20 μg/L 0.21 μg/g creat | |
| [ | Israel | 2011–2013 | Bedouin Arab mothers | 111 | 18–41 | - | 0.04 μg/L | |
| [ | China | 2014–2016 | Pregnant women | 1865 | 24–35 | 0.77 μg/L | - | |
| [ | France | 2011 | Pregnant women | 990 | >18 | - | 0.28 μg/L | |
|
| ||||||||
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 15.09 μg/L | 12.36 μg/L | |
| [ | Israel | 2013 | 140 | >18 | - | 7.6 μg/L | ||
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.12 μg/L | 0.09 μg/L | |
| [ | Italy (urban areas) | - | Healthy subjects | 44 | - | 0.003 μg/L | - | |
| [ | France | 2011 | Pregnant women | 990 | >18 | - | 0.04 μg/L | |
| [ | NHANES (USA) | 1999–2016 | Pregnant women | 404 | 15–44 | - | 0.079 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 2.70 μg/L | 1.87 μg/L | |
| [ | Israel | 2011–2013 | Bedouin Arab mothers | 111 | 18–41 | - | 1.29 μg/L | |
| [ | Puerto Rico | 2011–2017 | Pregnant women | 1285 | 18–40 | - | 2.5 μg/L | |
| [ | NHANES (USA) | 1999–2016 | Pregnant women | 404 | 15–44 | - | 2.01 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.01 μg/L | <LoQ | |
| [ | Israel | 2011–2013 | Bedouin Arab mothers | 111 | 18–41 | - | 0.11 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 4.88 μg/L | 4.16 μg/L | |
| [ | Italy (urban areas) | - | healthy subjects | 44 | - | 0.0054 μg/L | - | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.97 μg/L | 0.79 μg/L | |
| [ | China | 2012–2014 | Pregnant women | 800 | - | 6.35 μg/L | 3.35 μg/L | |
| [ | China | 2009–2010 | General population | 1647 | 6–60 | - | 2.85 μg/L | |
| [ | USA | 2003–2010 | Pregnant women | 1565 | 17–39 | - | 0.63 μg/L | |
| [ | USA | 2003–2004 | Pregnant women | 268 | 15–44 | - | 0.81 μg/L | |
| [ | Japan | 2007–2008 | Pregnant women | 78 | - | 1.19 μg/g creat | 0.48 μg/g creat | |
| [ | Australia | 2008–2010 | Pregnant women | 157 | 19–44 | 0.66 μg/L | - | |
| [ | Spain (Catalonia) | 2004–2006 | Pregnant women | 489 | >16 | 5.2 μg/g creat | - | |
| [ | Nigeria | 2006–2008 | Pregnant women | 214 | 17–49 | 28.5 μg/g creat | - | |
| [ | USA | 2011–2012 | Women | 1242 | >20 | - | 0.316 μg/L | |
| [ | Canada (Quebec) | 2009–2011 | Adults | 5738 | 6–79 | - | 0.52 μg/L | |
| [ | Belgium | 2010–2011 | Adults (n.o.) | 1022 | >18 | 0.74 μg/L | 15.4 μg/L | |
| [ | Riyadh (Saudi Arabia) | 2011–2013 | Lactating women | 204 | 19–45 | - | 5.04 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 5.52 μg/L | 4.41 μg/L | |
| [ | Italy (urban areas) | - | healthy subjects | 44 | - | 0.047 μg/L | ||
| [ | Japan (11 prefectures) | 2000–2005 | Women (n.o) | 1000 | 20–81 | - | 2.1 μg/L | |
| [ | Canada (Quebec) | 2009–2011 | Adults | 2992 | 6–79 | - | 1.30 μg/L | |
| [ | France | 2006–2007 | Adults | 2000 | 18–74 | - | 1.23 μg/L | |
| [ | Belgium | 2010–2011 | Adults (n.o) | 1022 | >18 | - | 1.73 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.02 μg/L | 0.01 μg/L | |
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.17 μg/L | 0.12 μg/L | |
| [ | China | 2014–2015 | Pregnant women | 598 | >20 | 0.17 μg/L | ||
|
| ||||||||
| Present study | Spain (Valencia) | 2015 | Women | 119 | 20–45 | 0.03 μg/L | 0.02 μg/L | |
| [ | NHANES (USA) | 2011–2016 | Women | - | 14–45 | - | 0.006 μg/g creat | |
| [ | New Mexico (USA) | 2010 | Pregnant women | 449 | 14–45 | - | 0.016 μg/g creat | |
AM: arithmetic mean; GM: geometric mean; n.o.: non-occupationally.